http://www.counterpunch.org/rost12042006.html
December 4, 2006
Dropping Like Flies From Torcetrapib
Clueless Pfizer Executives
By PETER ROST, MD
On Thursday, November 30, Pfizer's executives conducted a well
rehearsed dog-and-pony show over at Pfizer's research facilities in
Groton, CT. All interest was focused on torcetrapib; the most
important new drug in Pfizer's pipeline, which boosts good
cholesterol.
According to Forbes, Pfizer Chief Executive Jeffrey Kindler told about
250 analysts and investors attending the meeting that torcetrapib was
"one of the most important developments in our
generation."
Pfizer research president John LaMattina said, "We believe this
is the most important new development in cardiovascular medicine in
years," according to the Wall Street Journal.
On Saturday, December 2-two days later-Pfizer said in a statement that
it is terminating all clinical tests of torcetrapib and its plans to
bring the drug to market. A board of independent experts had reviewed
the latest data from a 15,000-patient test on torcetrapib and found
that patients on the drug were dying like flies; almost twice as many
dead as on the comparator. The company also said it is asking doctors
participating in studies of torcetrapib to tell patients to stop
taking the drug immediately.
Associated Press concluded, "The news is devastating to Pfizer,
which had been counting on the drug to revitalize stagnant sales that
have been hurt by numerous patent expirations on key products. It has
said it was spending around $800 million to develop
torcetrapib."
Of course, in the drug industry, bad stuff happens. But in this
particular case, the whole scientific world had been worried about the
fact that torcetrapib raises blood pressure. Not a good thing for a
cardiovascular drug. But that didn't stop the Pfizer executives from
hyping torcetrapib. Until it turned out that "one of the most
important developments in our generation" was really a killer
drug-quite literally.
And this is what makes Pfizer's CEO Mr. Kindler and Pfizer's research
chief Dr. LaMattina officially the most clueless executives in the
drug business.
Peter Rost, M.D., is a former Vice President of Pfizer. He
became well known in 2004 when he emerged as the first drug company
executive to speak out in favor of reimportation of drugs. He is the
author of "The Whistleblower, Confessions of a Healthcare
Hitman." See:
http://the-whistleblower-by-peter-rost.blogspot.com/